Electrospun Dextran Hemostatic Product for Deep Wound Access
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for achieving hemostasis in severe wounds, especially in inaccessible areas like penetrating injuries, are inadequate due to difficulties in delivering soluble hemostatic materials deep into the wound site, leading to incomplete clot formation and prolonged bleeding.
Innovation Solution
A method involving electrospun dextran fibers that dissolve upon contact with liquid, releasing thrombin and fibrinogen to initiate clotting, and a cylindrical hemostatic product design for deep wound access, allowing for the delivery of these agents directly to the wound site through a compressed configuration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional bandaging methods are used for penetrating wounds, then the wound site can be isolated and protected, but the hemostatic agents cannot be delivered deep into the inaccessible wound area
Solution Approach 1:
The patent uses a flexible, biodegradable polymer film impregnated with hemostatic agents that can be inserted into deep wounds. The thin film structure allows it to conform to and fill irregular wound cavities, enabling direct contact with bleeding surfaces that are inaccessible to conventional bandages.
Solution Approach 2:
The patent employs a biodegradable polymer that changes its physical properties over time - initially maintaining structural integrity for insertion and then progressively degrading to release hemostatic agents. This parameter change allows the material to transition from a delivery vehicle to an active therapeutic agent.
2Reliability
If soluble hemostatic materials are delivered deep into wounds, then hemostasis effectiveness improves, but the materials cannot be retained in place and remain soluble during storage
Solution Approach 1:
The patent uses a polymer that undergoes solubility parameter changes based on environmental conditions. The material is insoluble during storage and handling but becomes soluble when exposed to bodily fluids at the wound site, automatically transitioning from a stable delivery form to an active hemostatic form.
Solution Approach 2:
The patent employs a phase transition mechanism where the polymer matrix transitions from a solid, insoluble state during storage to a dissolved state upon contact with wound fluids. This phase change enables the material to remain stable during storage while becoming effective when needed.
3Reliability
If electrospun dextran fibers are used as a carrier, then the hemostatic agents can be delivered effectively, but the fibers must be processed through electrospinning which complicates manufacturing
Solution Approach 1:
The patent uses electrospinning parameters (voltage, flow rate, distance) to control fiber morphology and drug loading without requiring post-processing. By optimizing these parameters, the process directly produces the desired porous, high-surface-area fiber structure that enables effective drug delivery.
Solution Approach 2:
The patent creates composite electrospun fibers combining dextran with hemostatic agents during the electrospinning process itself. This integrated approach incorporates the therapeutic agents into the fiber structure without requiring separate loading steps, simplifying manufacturing while maintaining delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables rapid and effective hemostasis by ensuring immediate release of thrombin and fibrinogen at the wound site, reducing bleeding time and the need for additional interventions, while the cylindrical design facilitates deep wound treatment.
Implementation Method 1
electrospun dextran fibers that dissolve upon contact with liquid, releasing thrombin and fibrinogen
Implementation Method 2
releasing thrombin and fibrinogen to initiate clotting
Implementation Method 3
electrospun dextran fibers
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
A hemostatic product having a plurality of hemostatic layers. Each of the hemostatic layers includes a dextran support and at least one hemostatic agent, which is selected from the group consisting of thrombin and fibrinogen. The hemostatic layers are arranged in a stacked configuration. The hemostatic layers may include other biactive agents.